GE HealthCare (GEHC) valuation
GE HealthCare P/E ratio history
GE HealthCare trades at 16.2 times its earnings over the last twelve months and 14.3 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 18.0 (year to Dec 2024) to 25.5 (year to Dec 2023), with a median of 18.0.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $82.02 | $4.55 | 18.0 | 16.9 |
| Dec 31, 2024 | $78.18 | $4.34 | 18.0 | 17.1 |
| Dec 31, 2023 | $77.32 | $3.03 | 25.5 | 18.8 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
GE HealthCare valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| ResMedRMD | $33.4B | 20.9 | 18.6 | 5.9 |
| DexcomDXCM | $31.1B | 32.4 | 27.3 | 6.1 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| Edwards LifesciencesEW | $53.0B | 52.9 | 28.9 | 8.1 |
| SterisSTE | $22.2B | 27.8 | 19.8 | 3.7 |
| Becton DickinsonBDX | $54.5B | 74.5 | 15.1 | 2.6 |
| Boston ScientificBSX | $62.4B | 17.0 | 13.2 | 3.0 |
| Zimmer BiometZBH | $18.3B | 22.9 | 10.8 | 2.2 |
| Peer median | 30.1 | 19.2 | 4.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: GEHC financials · GEHC returns
No forecast, no recommendation. This page describes GE HealthCare from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.